Analysts Expect Cyclacel Pharmaceuticals Inc (CYCC) Will Announce Earnings of -$0.16 Per Share

Equities research analysts expect that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will post earnings of ($0.16) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Cyclacel Pharmaceuticals’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.18). The business is expected to announce its next earnings report on Monday, February 11th.

According to Zacks, analysts expect that Cyclacel Pharmaceuticals will report full-year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.67) to ($0.58). For the next year, analysts anticipate that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.82) to ($0.58). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Monday, November 12th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).

A number of equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 8th. HC Wainwright set a $7.00 target price on shares of Cyclacel Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 10th. LADENBURG THALM/SH SH assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Friday, September 7th. They set a “buy” rating and a $6.25 target price for the company. Roth Capital assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Wednesday, September 5th. They set a “buy” rating and a $8.00 target price for the company. Finally, ValuEngine upgraded shares of Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $5.63.

Shares of CYCC stock traded up $0.01 on Friday, reaching $0.90. 26,584 shares of the stock were exchanged, compared to its average volume of 59,894. Cyclacel Pharmaceuticals has a twelve month low of $0.85 and a twelve month high of $2.25.

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC increased its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 76,500 shares during the quarter. Renaissance Technologies LLC owned approximately 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent filing with the Securities & Exchange Commission. 5.50% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Featured Article: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit